Cooperative Agreement U01CA292741
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$586K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Cooperative Agreement
Place of Performance
Houston, TX 77005, USA
Similar Awards
This $643,363 Cooperative Agreement, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), will support a hybrid type III effectiveness-implementation trial to test best practices for deploying a "screen and treat" approach to cervical cancer screening using self-collected HPV DNA testing within HIV care and treatment facilities in Mozambique. The primary outcome is to increase the number of women screened and treated for...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,837,497 to New York University to conduct the KUPEWA project. The project aims to (A) identify optimal implementation strategies for increasing clinician recommendation of HPV vaccination for girls and young women aged 9-24 living with HIV in Malawi, (B) refine these strategies based on implementability, and (C) identify strategies that are effective,...
The National Cancer Institute (NCI) awarded a 5-year, $629,068 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to Albert Einstein College of Medicine to conduct an implementation study of integrated human papillomavirus (HPV) self-sampling in HIV care centers in Ethiopia. The study aims to leverage the Project ECHO (Extension for Community Healthcare Outcomes) virtual learning platform to promote experience sharing and technical assistance across 5 hospitals to improve...
The National Cancer Institute (NCI) awarded a 5-year, $706,365 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to The Trustees of Columbia University in the City of New York to implement the WHO-endorsed "screen, triage, and treat" (ISTAR) approach for cervical cancer screening among women living with HIV in La Romana, Dominican Republic. The project aims to sustain implementation of the ISTAR approach and generate new data to inform effective and equitable...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, aims to develop and evaluate an evidence-based, behavioral cervical cancer screening intervention for women living with HIV in Ghana. The $511,959 award to Baylor University will fund a hybrid effectiveness-implementation trial to integrate and scale up a home-based HPV self-sampling and communication model intervention called HOPE. The project seeks to...
The Cooperative Agreement awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $1,245,116 to Emory University from September 1, 2024 to August 31, 2029. The project, "Enhancing Cervical Cancer Screening and Treatment in Women Living with HIV in Kenya (ENHANCE Linkage)", aims to adapt and test implementation strategies to expand HIV care to screen for and treat early precancerous cervical cancer lesions in a...
The National Cancer Institute (NCI) awarded a $962,560 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Basic Health International Inc., a non-profit organization in Pittsburgh, Pennsylvania. The grant aims to modify and clinically validate the IRISTM device, a handheld thermal ablation device and digital colposcope designed for cervical cancer screening and treatment in low- and middle-income countries (LMIC). The key goals of the project are to: 1) Modify the IRISTM...
This federal Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, provides $592,027 to Northwestern University to develop and validate a point-of-care molecular diagnostic test for active hepatitis C virus (HCV) infection. The project aims to create a portable, low-cost device that can rapidly diagnose active HCV by detecting viral RNA, eliminating the need for two-step serologic and laboratory-based...
This $5,121,760.00 Cooperative Agreement award from the Centers for Disease Control and Prevention's (CDC) Global AIDS program (CFDA 93.067) supports comprehensive HIV/AIDS prevention, care, and treatment services in Nampula Province, Mozambique. The primary awardee, Servico Provincial De Saude De Nampula, a provincial health service organization in Mozambique, will use the funding over the 5-year project period from September 2024 to September 2029 to implement technical assistance, capacity...
This federal Cooperative Agreement award of $18,263,113.00 from the Centers for Disease Control and Prevention (CDC) Investigations and Technical Assistance program (CFDA 93.283) supports public health initiatives in Mozambique. The funding aims to enhance disease surveillance, conduct epidemiological investigations, build laboratory capacity, improve public health communications, and provide technical assistance to strengthen the health system and address health disparities. The Ministry of...